BDTX — Black Diamond Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1701541 ·
Last close
$1.44
Market Cap
$82.75M
52W High
$4.06
52W Low
$1.39
ADV30
842,602
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -12,122,000 | -10,012,000 | 115,561,000 | 15,084,000 | 27,483,000 |
| Jun 2026 | 0 | — | -12,057,000 | -9,905,000 | 125,029,000 | 19,194,000 | 28,938,000 |
| Mar 2026 | 0 | — | -11,259,000 | -9,036,000 | 132,922,000 | 30,071,000 | 28,622,000 |
| Dec 2025 | 0 | — | -10,262,000 | -15,116,000 | 143,010,000 | 20,990,000 | 30,799,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,325,000
Investing CF
$17,705,000
Financing CF
$-152,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-493,693,000
Inventory
—
Receivables
—
ST Investments
$86,946,000
EBIT TTM
$-45,700,000
Pretax Income TTM
$-44,069,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-45,551,000
Free Cash Flow
$-23,302,500
Enterprise Value
$-1,515,665
Total Cash
$102,030,000
Total Debt
$16,036,000
Shares Out
57,468,255
Trailing EPS
$-0.77
Book Value
$1.53
ROE
-41.1%
ROA
-20.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 70,000,000 | 19,870,000 | 22,367,000 | 143,010,000 | 30,799,000 | 112,211,000 | 29,614,000 |
| Dec 2024 | 0 | -78,781,000 | -69,676,000 | 122,640,000 | 39,355,000 | 83,285,000 | -62,303,000 |
| Dec 2023 | 0 | -86,460,000 | -82,442,000 | 158,567,000 | 41,831,000 | 116,736,000 | -66,717,000 |
| Dec 2022 | 0 | -92,828,000 | -91,169,000 | 156,255,000 | 40,560,000 | 115,695,000 | -85,082,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-42,555,000
OpCashFlow TTM
—
Assets (Latest)
$125,029,000
Forward EPS
$-1.02
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $1.43 · call volume: 212 · put volume: 4
Expected Move to 2027-03-19:
±$1.27
(88.81%) —
implied range
$0.16 –
$2.70
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VXRT | Vaxart, Inc. | $86.51M | $0.35 | — |
| OTLK | Outlook Therapeutics, Inc. | $87.79M | $0.36 | — |
| CLLS | Cellectis S.A. | $77.08M | $1.06 | — |
| CHRS | Coherus Oncology, Inc. | $73.95M | $0.48 | — |
| TNYA | Tenaya Therapeutics, Inc. | $73.58M | $0.32 | — |
News headlines (Yahoo Finance, 1h cache)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
2026-11-12 21:01 · Yahoo
Black Diamond: Q3 Earnings Snapshot
2026-11-10 11:37 · Yahoo
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
2026-11-10 11:30 · Yahoo
Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
2026-11-09 21:01 · Yahoo
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:01 · Yahoo
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-05 20:01 · Yahoo
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
2026-05-21 23:09 · Yahoo
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
2026-05-27 15:13 · Yahoo
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
2026-05-19 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.